Exogenous administration of thiosulfate, a donor of hydrogen sulfide, attenuates angiotensin II-induced hypertensive heart disease in rats

British Journal of Pharmacology

Volumn 172, Issue 6, 2015, Pages 1494-1504

  Snijder, P M ^a   Frenay, A R ^a   De Boer, R A ^a   Pasch, A ^b   Hillebrands, J L ^a   Leuvenink, H G D ^a   Van Goor, H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; CALCIUM; FIBRONECTIN; GALECTIN 3; HYDROGEN SULFIDE; MESSENGER RNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SODIUM HYDROSULFIDE; SODIUM THIOSULFATE; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; SODIUM BISULFIDE; SULFIDE; THIOSULFATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHROPOMETRIC PARAMETERS; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; GENE EXPRESSION; HEART INJURY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART TO BODY WEIGHT RATIO; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; SYSTOLIC BLOOD PRESSURE; ANIMAL; BLOOD PRESSURE; CARDIOMEGALY; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOMEGALY; DISEASE MODELS, ANIMAL; HYDROGEN SULFIDE; HYPERTENSION; MALE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; SULFIDES; THIOSULFATES;

EID: 84923765047     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12825     Document Type: Article

References (58)

1. Abe K, Kimura H, (1996). The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci 16: 1066-1071.
2. Agarwal R, Campbell RC, Warnock DG, (2004). Oxidative stress in hypertension and chronic kidney disease: role of angiotensin II. Semin Nephrol 24: 101-114.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Ion channels. Br J Pharmacol 170: 1607-1646.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
6. Asplin JR, Donahue SE, Lindeman C, Michalenka A, Strutz KL, Bushinsky DA, (2009). Thiosulfate reduces calcium phosphate nephrolithiasis. J Am Soc Nephrol 20: 1246-1253.
7. de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ, (2009). Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 11: 811-817.
8. Bos EM, Wang R, Snijder PM, Boersema M, Damman J, Fu M, et al. (2013). Cystathionine gamma-lyase protects against renal ischemia/reperfusion by modulating oxidative stress. J Am Soc Nephrol 24: 759-770.
9. Brinson AE, Harding T, Diliberto PA, He Y, Li X, Hunter D, et al. (1998). Regulation of a calcium-dependent tyrosine kinase in vascular smooth muscle cells by angiotensin II and platelet-derived growth factor. Dependence on calcium and the actin cytoskeleton. J Biol Chem 273: 1711-1718.
10. Cicone JS, Petronis JB, Embert CD, Spector DA, (2004). Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis 43: 1104-1108.
11. Drazner MH, (2011). The progression of hypertensive heart disease. Circulation 123: 327-334.
12. Du J, Peng T, Scheidegger KJ, Delafontaine P, (1999). Angiotensin II activation of insulin-like growth factor 1 receptor transcription is mediated by a tyrosine kinase-dependent redox-sensitive mechanism. Arterioscler Thromb Vasc Biol 19: 2119-2126.
13. Farese S, Stauffer E, Kalicki R, Hildebrandt T, Frey BM, Frey FJ, et al. (2011). Sodium thiosulfate pharmacokinetics in hemodialysis patients and healthy volunteers. Clin J Am Soc Nephrol 6: 1447-1455.
14. Hayden MR, Goldsmith DJ, (2010). Sodium thiosulfate: new hope for the treatment of calciphylaxis. Semin Dial 23: 258-262.
15. Hayden MR, Tyagi SC, Kolb L, Sowers JR, Khanna R, (2005). Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol 4: 4.
16. Hildebrandt TM, Grieshaber MK, (2008). Three enzymatic activities catalyze the oxidation of sulfide to thiosulfate in mammalian and invertebrate mitochondria. FEBS J 275: 3352-3361.
17. Jia L, Li Y, Xiao C, Du J, (2012). Angiotensin II induces inflammation leading to cardiac remodeling. Front Biosci (Landmark Ed) 17: 221-231.
18. Jiang HL, Wu HC, Li ZL, Geng B, Tang CS, (2005). Changes of the new gaseous transmitter H2S in patients with coronary heart disease. Di Yi Jun Yi Da Xue Xue Bao 25: 951-954.
19. Kabil O, Banerjee R, (2010). Redox biochemistry of hydrogen sulfide. J Biol Chem 285: 21903-21907.
20. Kimura Y, Kimura H, (2004). Hydrogen sulfide protects neurons from oxidative stress. FASEB J 18: 1165-1167.
21. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
22. Kimura Y, Goto Y, Kimura H, (2010). Hydrogen sulfide increases glutathione production and suppresses oxidative stress in mitochondria. Antioxid Redox Signal 12: 1-13.
23. Koitabashi N, Kass DA, (2011). Reverse remodeling in heart failure-mechanisms and therapeutic opportunities. Nat Rev Cardiol 9: 147-157.
24. Kondo K, Bhushan S, King AL, Prabhu SD, Hamid T, Koenig S, et al. (2013). H(2)S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase. Circulation 127: 1116-1127.
25. Kovacic D, Glavnik N, Marinsek M, Zagozen P, Rovan K, Goslar T, et al. (2012). Total plasma sulfide in congestive heart failure. J Card Fail 18: 541-548.
26. Lassegue B, Griendling KK, (2010). NADPH oxidases: functions and pathologies in the vasculature. Arterioscler Thromb Vasc Biol 30: 653-661.
27. Lu M, Liu YH, Goh HS, Wang JJ, Yong QC, Wang R, et al. (2010). Hydrogen sulfide inhibits plasma renin activity. J Am Soc Nephrol 21: 993-1002.
28. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
29. Mann DL, (2002). Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91: 988-998.
30. Mervaala E, Muller DN, Schmidt F, Park JK, Gross V, Bader M, et al. (2000). Blood pressure-independent effects in rats with human renin and angiotensinogen genes. Hypertension 35: 587-594.
31. Mullan BA, Young IS, Fee H, McCance DR, (2002). Ascorbic acid reduces blood pressure and arterial stiffness in type 2 diabetes. Hypertension 40: 804-809.
32. Mustafa AK, Sikka G, Gazi SK, Steppan J, Jung SM, Bhunia AK, et al. (2011). Hydrogen sulfide as endothelium-derived hyperpolarizing factor sulfhydrates potassium channels. Circ Res 109: 1259-1268.
33. Olson KR, Deleon ER, Gao Y, Hurley K, Sadauskas V, Batz C, et al. (2013). Thiosulfate: a readily accessible source of hydrogen sulfide in oxygen sensing. Am J Physiol Regul Integr Comp Physiol 305: 592-603. 10.1152/ajpregu.00421
34. O'Neill WC, Hardcastle KI, (2012). The chemistry of thiosulfate and vascular calcification. Nephrol Dial Transplant 27: 521-526.
35. Pasch A, Schaffner T, Huynh-Do U, Frey BM, Frey FJ, Farese S, (2008). Sodium thiosulfate prevents vascular calcifications in uremic rats. Kidney Int 74: 1444-1453.
36. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-1106.
37. Racasan S, Braam B, van der Giezen DM, Goldschmeding R, Boer P, Koomans HA, et al. (2004). Perinatal L-arginine and antioxidant supplements reduce adult blood pressure in spontaneously hypertensive rats. Hypertension 44: 83-88.
38. Rathaus M, Bernheim J, (2002). Oxygen species in the microvascular environment: regulation of vascular tone and the development of hypertension. Nephrol Dial Transplant 17: 216-221.
39. Roy A, Khan AH, Islam MT, Prieto MC, Majid DS, (2012). Interdependency of cystathione gamma-lyase and cystathione beta-synthase in hydrogen sulfide-induced blood pressure regulation in rats. Am J Hypertens 25: 74-81.
40. Sen U, Vacek TP, Hughes WM, Kumar M, Moshal KS, Tyagi N, et al. (2008). Cardioprotective role of sodium thiosulfate on chronic heart failure by modulating endogenous H2S generation. Pharmacology 82: 201-213.
41. Sen U, Munjal C, Qipshidze N, Abe O, Gargoum R, Tyagi SC, (2010). Hydrogen sulfide regulates homocysteine-mediated glomerulosclerosis. Am J Nephrol 31: 442-455.
42. Shahbaz AU, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC, McGee JE, et al. (2010). Fibrosis in hypertensive heart disease: molecular pathways and cardioprotective strategies. J Hypertens 28 (Suppl. 1): S25-S32.
43. Shibuya N, Koike S, Tanaka M, Ishigami-Yuasa M, Kimura Y, Ogasawara Y, et al. (2013). A novel pathway for the production of hydrogen sulfide from D-cysteine in mammalian cells. Nat Commun 4: 1366.
44. Shirozu K, Tokuda K, Marutani E, Lefer D, Wang R, Ichinose F, (2014). Cystathionine γ-lyase deficiency protects mice from galactosamine/lipopolysaccharide-induced acute liver failure. Antioxid Redox Signal 20: 204-216.
45. Singh RP, Derendorf H, Ross EA, (2011). Simulation-based sodium thiosulfate dosing strategies for the treatment of calciphylaxis. Clin J Am Soc Nephrol 6: 1155-1159.
46. Singh S, Padovani D, Leslie RA, Chiku T, Banerjee R, (2009). Relative contributions of cystathionine beta-synthase and gamma-cystathionase to H2S biogenesis via alternative trans-sulfuration reactions. J Biol Chem 284: 22457-22466.
47. Snijder PM, de Boer RA, Bos EM, van den Born JC, Ruifrok WP, Vreeswijk-Baudoin I, et al. (2013). Gaseous hydrogen sulfide protects against myocardial ischemia-reperfusion injury in mice partially independent from hypometabolism. PLoS ONE 8: e63291.
48. Szabo G, Veres G, Radovits T, Gero D, Modis K, Miesel-Groschel C, et al. (2011). Cardioprotective effects of hydrogen sulfide. Nitric Oxide 25: 201-210.
49. Thomas JE, McGinnis G, (2002). Safety of intraventricular sodium nitroprusside and thiosulfate for the treatment of cerebral vasospasm in the intensive care unit setting. Stroke 33: 486-492.
50. Tokuda K, Kida K, Marutani E, Crimi E, Bougaki M, Khatri A, et al. (2012). Inhaled hydrogen sulfide prevents endotoxin-induced systemic inflammation and improves survival by altering sulfide metabolism in mice. Antioxid Redox Signal 17: 11-21.
51. Ubuka T, Abe T, Kajikawa R, Morino K, (2001). Determination of hydrogen sulfide and acid-labile sulfur in animal tissues by gas chromatography and ion chromatography. J Chromatogr B Biomed Sci Appl 757: 31-37.
52. Wang R, (2002). Two's company, three's a crowd: can H2S be the third endogenous gaseous transmitter? FASEB J 16: 1792-1798.
53. Wynn TA, (2008). Cellular and molecular mechanisms of fibrosis. J Pathol 214: 199-210.
54. Yang G, Wu L, Jiang B, Yang W, Qi J, Cao K, et al. (2008). H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science 322: 587-590.
55. Yu L, Ruifrok WP, Meissner M, Bos EM, van Goor H, Sanjabi B, et al. (2013). Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 6: 107-117.
56. Zhao W, Wang R, (2002). H(2)S-induced vasorelaxation and underlying cellular and molecular mechanisms. Am J Physiol Heart Circ Physiol 283: H474-H480.
57. Zhao X, Zhang LK, Zhang CY, Zeng XJ, Yan H, Jin HF, et al. (2008). Regulatory effect of hydrogen sulfide on vascular collagen content in spontaneously hypertensive rats. Hypertens Res 31: 1619-1630.
58. Zhong G, Chen F, Cheng Y, Tang C, Du J, (2003). The role of hydrogen sulfide generation in the pathogenesis of hypertension in rats induced by inhibition of nitric oxide synthase. J Hypertens 21: 1879-1885.